Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Flu Vaccines
New flu vaccines study results reported from S.L. Block et al
October 29th, 2008
Investigators publish new data in the report 'Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.' According to a study from the United States, "Live attenuated influenza vaccine (LAIV) is indicated for influenza prevention in persons 2-49 years of age. This study describes the incidence and duration of vaccine virus shedding and serum immune responses after receipt of LAIV." "A single open-label dose of trivalent LAIV was administered intranasally to 344 subjects in 3 age cohorts: 5-8, 9-17, and 18-49 years of age. Shedding was determined by culture of nasal swabs (on days 1-7, daily; days 9-25, every other day; and day...
Source: Vaccine Weekly (2008-10-29)
|
